帕罗西汀增加CYP2D6广泛但不差代谢者(R)美沙酮的稳态浓度。
文章的细节
-
引用
-
S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB
帕罗西汀增加CYP2D6广泛但不差代谢者(R)美沙酮的稳态浓度。
临床精神药理学杂志。2002年4月22(2):211-5。
- PubMed ID
-
11910269 (在PubMed]
- 摘要
-
在10名接受美沙酮维持治疗的成瘾患者平均12天内,分别在服用帕罗西汀20mg /d前后测定(R)-美沙酮(即活性形态)、(S)-美沙酮和(R,S)-美沙酮稳态血药浓度。8例患者基因分型为CYP2D6纯合子广泛代谢者(EMs), 2例患者基因分型为差代谢者(PMs)。帕罗西汀显著增加了整个组美沙酮两种对映体的浓度((R)-美沙酮+/- SD平均增加26 +/- 32%;范围:-14% ~ +83%,p = 0.032;(S)-美沙酮,49 +/- 51%;范围,-29% ~ +137%,p = 0.028;(R,S)-美沙酮,35±41%;范围,-20% ~ +112%,p = 0.032), 8个EMs组(平均增加32%,p = 0.036;53%, p = 0.028;(R)-美沙酮、(S)-美沙酮和(R,S)-美沙酮分别为42%,p = 0.036)。 On the other hand, in the two PMs, (S)-methadone but not (R)-methadone concentrations were increased by paroxetine (mean increases of 36% and 3%, respectively). Paroxetine is a strong CYP2D6 inhibitor, and these results confirm previous studies showing an involvement of CYP2D6 in methadone metabolism with a stereoselectivity toward the (R)-enantiomer. Because paroxetine is a mild inhibitor of CYP1A2, CYP2C9, CYP2C19, and CYP3A4, increase of (S)-methadone concentrations in both EMs and PMs could be mediated by inhibition of any of these isozymes.
引用这篇文章的药库数据
- 药物酶
-
药物 酶 种类 生物 药理作用 行动 帕罗西汀 细胞色素P450 1 a2 蛋白质 人类 未知的底物抑制剂细节 干扰素alfa-2a 细胞色素P450 1 a2 蛋白质 人类 未知的抑制剂细节